American Heart Journal
Volume 143, Issue 5 , Pages 748-752 , May 2002

Enoxaparin in acute coronary syndromes: Evidence for superiority over placebo or untreated control

Received 3 May 2001 ,Accepted 16 November 2001.

References 

  1. Fuster V, Badimon L, Badimon JJ, et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242–250
  2. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation. 1998;97:1195–1206
  3. Antiplatelet Trialists' Collaboration . Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–106
  4. Oler A, Whooley MA, Oler J, et al.  Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276:811–815
  5. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  6. Eikelboom JW, Anand SS, Malmberg K, et al.  Unfractionated heparin and low-molecular weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942
  7. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698
  8. Hirsh J, Warkentin TE, Raschke R, et al.  Heparin and low-molecular-weight heparin: mechanism of action, dosing, considerations, monitoring, efficacy, and safety. Chest. 1998;114:489S–510S
  9. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation. 1998;98:1575–1582
  10. Gurfinkel EP, Manos El, Mejail RI, et al.  LMWH versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 1995;26:313–318
  11. Fragmin during Instabiliry in Coronary Artery Disease FRISC study group . Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 1996;347:561–568
  12. Fragmin and fast revascularization during instability in coronary artery disease FRISC II investigators . Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:701–707
  13. Klein W, Buchwald A, Hillis SE, et al.  Fragmin in unstable coronary artery disease study: comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation. 1997;96:61–68
  14. Cohen M, Demers C, Gurfinkel EP, et al.  A comparison of low- molecular-weight heparin with UFH for unstable coronary artery disease: Efficacy and Safety of Subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337:447–452
  15. Antman EM, McCabe CH, Gurfinkel EP, et al.  Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TlMI) IIB trial. Circulation. 1999;100:1593–1601
  16. The FRAXIS Study Group . Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J. 1999;20:1553–1562
  17. Fisher LD, Gent M, Buller HR. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J. 2000;141:26–32
  18. Yusuf S, Peto R, Lewis J, et al.  Beta blockade during and after MI: an overview of the randomized trials. Prog Cardiovascular Dis. 1985;27:335–371
  19. Theroux P, Ouimet H, McCans J, et al.  Aspirin, heparin, or both to treat acute unstable angina. N Bngl J Med. 1988;319:1105–1111
  20. Cohen M, Adams PC, Hawkins L, et al.  Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol. 1990;66:1287–1292
  21. The RISC Group . Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827–830
  22. Cohen M, Adams PC, Parry G, et al.  Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation. 1994;89:81–88
  23. Holdright D, Patel D, Cunningham D, et al.  Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 1994;24:39–45
  24. Antman EM, Cohen M, Radley D, et al.  Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI11B-ESSENCE meta-analysis. Circulation. 1999;100:1602–1608
  25. Simon R. Bayesian design and analysis of active control clinical trials. Biometrics. 1999;55:484–487

☆ Guest editor for this manuscript was Carl J. Pepine, MD, University of Florida College of Medicine, Gainesville, Fla.

☆☆ Reprint requests: David Massel, MD, FRCPC, London Health Sciences Centre, Rm 205, Colborne Bldg, Victoria Campus, 375 South St, London, Ontario, Canada N6A 4G5.

★ E-mail: dmassel@lhsc.on.ca

PII: S0002-8703(02)40447-4

doi: 10.1067/mhj.2002.121808

American Heart Journal
Volume 143, Issue 5 , Pages 748-752 , May 2002

Article Tools

* Image Usage & Resolution